Devi S J, Hayat U, Powell J L, Morris J G
Division of Bacterial Products, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland 20892.
Infect Immun. 1996 Jun;64(6):2220-4. doi: 10.1128/iai.64.6.2220-2224.1996.
Vibrio vulnificus is an oyster-associated bacterial pathogen that causes life-threatening fulminating septicemia and necrotizing wound infections in humans. The capsular polysaccharide of V. vulnificus (VvPS) is critical for virulence. Previously we showed that active immunization of mice with a VvPS-tetanus toxoid (VvPS-TTa) conjugate vaccine conferred significantly higher protection against subsequent lethal challenge than immunization with VvPS alone. In the current study, we examined the utility of immunoprophylaxis or immunotherapy with hyperimmune antisera elicited by VvPS-TTa and VvPS-TTb conjugate vaccines prepared by different synthetic schemes. First we demonstrated that the Ribi adjuvant significantly enhanced the murine antibody response (P < or = 0.02) to both conjugates. Subsequently, high-titered polyclonal antisera were raised to VvPS-TTa and VvPS-TTb conjugate vaccines by using Ribi adjuvant or Freund's adjuvants. Antisera were observed to have protective effects when administered before and after acute lethal infection. All animals receiving prophylactic antisera intraperitoneally 24 h before lethal challenge with homologous carbotype 1 were protected, while 73 to 100% of control mice succumbed. Immunotherapy was also effective, with survival rates of 60 to 73% seen among mice when antisera were administered 2 h after bacterial challenge, at a time when symptoms of infection were already apparent. The protective effect of capsular antiserum appeared to be serotype specific. Antisera to the, carbotype 1 VvPS-TTa vaccine did not confer cross-protection against lethal challenge with carbotype 2 V. vulnificus despite partial structural similarity and a weak serological cross-reaction between the two carbotypes. Immune globulins induced by a potential multivalent VvPS conjugate vaccine composed of clinically prevalent carbotypes may have utility in the management of V. vulnificus infections and deserve further evaluation.
创伤弧菌是一种与牡蛎相关的细菌病原体,可导致人类危及生命的暴发性败血症和坏死性伤口感染。创伤弧菌的荚膜多糖(VvPS)对其毒力至关重要。此前我们发现,用VvPS-破伤风类毒素(VvPS-TTa)结合疫苗对小鼠进行主动免疫,比单独用VvPS免疫能提供更高的保护,以抵御随后的致死性攻击。在本研究中,我们检测了由不同合成方案制备的VvPS-TTa和VvPS-TTb结合疫苗引发的超免疫抗血清用于免疫预防或免疫治疗的效用。首先,我们证明了Ribi佐剂能显著增强小鼠对两种结合物的抗体反应(P≤0.02)。随后,通过使用Ribi佐剂或弗氏佐剂,产生了针对VvPS-TTa和VvPS-TTb结合疫苗的高滴度多克隆抗血清。观察到抗血清在急性致死性感染前后给药时均具有保护作用。在致死性攻击前24小时腹腔内注射同源1型菌的预防性抗血清的所有动物均受到保护,而73%至100%的对照小鼠死亡。免疫治疗也有效,在细菌攻击后2小时给予抗血清时,小鼠的存活率为60%至73%,此时感染症状已经明显。荚膜抗血清的保护作用似乎具有血清型特异性。尽管两种菌型之间存在部分结构相似性和微弱的血清学交叉反应,但1型菌VvPS-TTa疫苗的抗血清对2型创伤弧菌的致死性攻击没有提供交叉保护。由临床流行菌型组成的潜在多价VvPS结合疫苗诱导的免疫球蛋白可能在创伤弧菌感染的管理中有用,值得进一步评估。